165
Views
9
CrossRef citations to date
0
Altmetric
Original Research

The Immune-Related Gene ELF3 is a Novel Biomarker for the Prognosis of Ovarian Cancer

ORCID Icon, , , ORCID Icon & ORCID Icon
Pages 5537-5548 | Published online: 10 Sep 2021

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
  • Chen B, Liu S, Wang H, Li G, Lu X, Xu H. Differential expression profiles and function prediction of transfer RNA-derived fragments in high-grade serous ovarian cancer. Biomed Res Int. 2021;2021:5594081.
  • Boussios S, Moschetta M, Zarkavelis G, Papadaki A, Kefas A, Tatsi K. Ovarian sex-cord stromal tumours and small cell tumours: pathological, genetic and management aspects. Crit Rev Oncol Hematol. 2017;120:43–51. doi:10.1016/j.critrevonc.2017.10.007
  • Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290(5):839–842. doi:10.1007/s00404-014-3364-8
  • Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061.
  • Wasylyk B, Hagman J, Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci. 1998;23(6):213–216. doi:10.1016/S0968-0004(98)01211-0
  • Larsen S, Kawamoto S, Tanuma S, Uchiumi F. The hematopoietic regulator, ELF-1, enhances the transcriptional response to Interferon-β of the OAS1 anti-viral gene. Sci Rep. 2015;5(1):17497. doi:10.1038/srep17497
  • Enfield KSS, Marshall EA, Anderson C, et al. Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. Nat Commun. 2019;10(1):5438. doi:10.1038/s41467-019-13295-y
  • Chen H, Chen W, Zhang X, et al. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer. Oncol Rep. 2019;41(1):570–578.
  • Kar A, Koto K, Walker D, et al. ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR(+)HER2(+) breast cancer patients. Breast Cancer Res Treat. 2020;182(3):601–612. doi:10.1007/s10549-020-05734-y
  • Wang JL, Chen ZF, Chen HM, et al. Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death Dis. 2014;5(5):e1263. doi:10.1038/cddis.2014.206
  • Takaoka A, Ishikawa T, Okazaki S, et al. ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer. In Vivo (Brooklyn). 2021;35(1):191–201. doi:10.21873/invivo.12248
  • Lu X, Li G, Liu S, Wang H, Zhang Z, Chen B. Bioinformatics analysis of KIF1A expression and gene regulation network in ovarian carcinoma. Int J Gen Med. 2021;14:3707–3717. doi:10.2147/IJGM.S323591
  • Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–316. doi:10.1038/nbt.3772
  • Chen J, Tang H, Li T, et al. Comprehensive analysis of the expression, prognosis, and biological significance of OVOLs in breast cancer. Int J Gen Med. 2021;14:3951–3960. doi:10.2147/IJGM.S326402
  • Chen T, Zhu C, Wang X, Pan Y. LncRNA ELF3-AS1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021;2021:8323487. doi:10.1155/2021/8323487
  • Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e411.
  • Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
  • Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
  • Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
  • Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
  • Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
  • Sun T, Bi F, Liu Z, Yang Q. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer. Aging. 2020;12(13):13281–13296. doi:10.18632/aging.103433
  • Sieńko J, Teliga-Czajkowska J, Przytula E, Czajkowski K, Smolarczyk R, Nowis D. Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer. Ann Agric Environ Med. 2019;26(3):415–419. doi:10.26444/aaem/105899
  • Cao T, Pan W, Sun X, Shen H. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-A bioinformatics integrative analysis. J Ovarian Res. 2019;12(1):101.
  • Sun Z, Sun L, He M, Pang Y, Yang Z, Wang J. Low BCL7A expression predicts poor prognosis in ovarian cancer. J Ovarian Res. 2019;12(1):41. doi:10.1186/s13048-019-0518-0
  • Bu H, Li Y, Jin C, et al. Overexpression of PRC1 indicates a poor prognosis in ovarian cancer. Int J Oncol. 2020;56(3):685–696.
  • Kong L, Liu P, Zheng M, et al. The miR-1224-5p/ELF3 axis regulates malignant behaviors of pancreatic cancer via PI3K/AKT/notch signaling pathways. Onco Targets Ther. 2020;13:3449–3466. doi:10.2147/OTT.S248507
  • Zhao W, Sun Q, Yu Z, et al. MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. Gene. 2018;670:31–37. doi:10.1016/j.gene.2018.05.100
  • Demircan NC, Boussios S, Tasci T, Öztürk MA. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med. 2020;8(24):1714. doi:10.21037/atm-20-4499